Aerocrine and EMR Leader Meditab form Strategic Alliance for Allergy Offices
SOLNA, Sweden – 16 March 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the launch of a strategic alliance with Meditab Software Inc. at the American Association of Allergy, Asthma and Immunology annual meeting in San Francisco on March 19-21.
Aerocrine and Meditab join forces for the Allergy offices across the US. Meditab, based in northern California, is an industry leader in providing fully integrated and certified electronic health records and practice management solutions for physicians throughout the US. They supply a unique electronic medical records (EMR) product for the Allergists, a primary call point for Aerocrine, that will now also comprise measurements of airway inflammation performed with NIOX MINO.
“Meditab Software has always been dedicated in providing unique features in its medical software products to increase the productivity of clinical staff and to improve patient safety.
As a leader in providing a complete solution for Allergists and Pulmonologists, we are very excited to offer an integration with Aerocrine’s NIOX MINO. This integration will allow the providers to accurately record and trend FENO data directly within the electronic medical records to improve patient outcome,” said Kal Patel, Meditab’s Chief Operating Officer.
“Aerocrine’s revolutionary technology of measuring airway inflammation in asthma management is gaining rapid acceptance with Allergists,” said Kathy Hodgdon, Aerocrine Inc’s Director of Sales and Marketing. “The ability to directly transfer test results into the patient’s electronic medical record is valuable and now this can be achieved by the Meditab alliance.”
Asthma is a chronic inflammatory disease where an inflammation of the airways causes increased sensitivity to asthma triggers. The disease affects more than 22 million Americans, including more than six million children. Aerocrine’s founders made the original discovery that levels of nitric oxide in exhaled breath, FENO, is elevated in patients with asthma. The company has since pioneered the development of medical devices to monitor airway inflammation by measuring FENO. NIOX MINO, the first handheld device for FENO monitoring in clinical practice, received FDA clearance in 2008. To date, more than four million patient tests have been performed around the world using Aerocrine’s NIOX products.
For more information, please visit www.aerocrine.com or contact:
Paul de Potocki, CEO Aerocrine AB, telephone: +46 8 629 0780
Chip Neff, President, Aerocrine Inc., telephone: +1 (919) 696-4267
About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.
About NIOX MINO
NIOX MINO® received 510(K) market clearance from the U.S. Food and Drug Administration (FDA) for clinical use in May 2008. NIOX MINO is a hand-held device that provides accurate, reproducible, and immediate measurement of fractional exhaled nitric oxide (FENO), a validated method for assessing asthma-related airway inflammation.
NIOX MINO can be used in the doctor’s office to provide a non-invasive assessment of airway inflammation. NIOX MINO is a tool offering people suffering from inflammatory airway disease personalized inflammation control. Its use is reimbursable in the U.S. through CPT code 95012.
For more information about NIOX MINO, and to view a video demonstration of how to use the device, please visit www.nioxmino.com or call (866) 275-6469.
About Meditab Software, Inc.
Since 1998, Meditab Software, Inc. has developed automated clinical management solutions that maximize productivity, improve patient care, and reduce costs. Meditab develops and supports a multi award-winning and certified solution that combines Practice Management, EHR, and Document Imaging in one integrated system at an affordable cost. Meditab takes tremendous pride in its ability to provide comprehensive, user-friendly, federally compliant solutions for our clients' unique needs.
For more information, please visit www.meditab.com/practice-on or call 866-99-Go-EMR.
Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 11:00 a.m. on March the 16th 2011.